Let's see how the charts are shaping up ahead of the numbers Friday.
Let's see how far this pharma name could fall, even as it plays a leading role in the battle against the pandemic.
Here's where profit taking should be considered.
Let's check the charts and indicators.
Here's how traders can play the stock.
Traders could go long ISRG at current levels.
All eyes will be on JNJ as it releases its numbers Tuesday.
Stand aside and let things "shake out".
A double in five months has my attention.
The current candidates for the 2022 Tax-Loss Selling Recovery Portfolio are few and far between, with only a couple households names in the bunch.